

Application of Palliative Medicine in Head Neck cancers

Sushmita Ghoshal

Prof.& Head, Radiotherapy

PGIMER< Chandigarh



Approach to symptom management

PHYSICAL



SOCIAL

SPIRITUAL

Physical symptoms

Disease related

Treatment related

Debility related

Unrelated

SYMPTOMS ARE INTER-RELATED!

Correlation of

symptoms



Disease related symptoms



- Pain
- Difficulty in
 - Chewing
 - Swallowing
 - Breathing
- Bleeding
- Fungation

EXPERIENCE AT PGI, CHANDIGARH

- Split course radiation, 35Gy/15# -→25Gy/10# for responders (audit data 45% CR, median PFS 12m, OS 16m)
- Shorter regime 30Gy/ 10# → supplement for responders (objective)
- When evaluated after 4 weeks of radiation
 - >50% symptom relief for pain, dysphagia, dyspnea, cough, disturbed sleep
 - No grade 3 mucositis
 - Relief lasted for about 3 months
 - Patients who came for follow up had progression of disease at a median time of 6 months

Quad shot



Sushmita Ghoshal Philip Kuttikat Satyawati Mohindra

Quad Shot: an effective course of palliative radiation

Comparing two-day schedule with conventional two weeks radiation



- Initial experience 67% RR
- Randomised trial comparing with conventional 30Gy/ 10#
 - Comparable symptom relief, response rate and overall QOL
 - Conventional RT 24%
 grade 3 mucositis and 36%
 grade 2 dermatitis. NONE
 in Quad Shot!
 - PFS and overall survival better in conventional (difference of one month)

PALLIATIVE RT – Review Article

Talapatra et al 2006

Author [ref]	No. of pts (n)	Dose/fx (cGy)	No. of	Fx/day	Total dose (Gy)	Overall Outcome treatment /comment time
Erkal ^[19]	40	300 cGy	10	OD	30 Gy	2 weeks One yr response 77%
		1000 cGy	2	OD	20 Gy	1 week One yr response 48%
Lusinchi ^[20]	54	200 cGy	15	OD	30 Gy	3 weeks 33% discontinued RT
Wendt ^[22]	34	180 cGy	39	BID	70.2 Gy	51 days Palliation similar (3 cycles to historic controls every 3-4 wks)
Paris ^[24]	37	370 cGy	12	BID	44 Gy	9 weeks Majority achieved good (3 cycles palliation every 3-wks)
Minatel ^[25]	58	250 cGy	20	OD	50 Gy	6 weeks Symptom relief in 81% (2 weeks break after 25 Gy
Ghoshal ^[26]	25	300 cGy	10	OD	30 Gy	2 weeks Significant symptom relief
Mohanti ^[27]	505	400 cGy	5	OD	20 Gy	1 week Symptom relief >50%
Corrya ^[28]	30	350 cGy	4	BD	42 Gy	2 consecutive Objective response in days (3 cycles 53% with improved every 4wks) QOL
Weissberg ^[29]	64	400 cGy 200 cGy	10-12 30-35	OD OD	40-48 Gy 60-70 Gy	2-2.5 weeks Comparable 6-7 weeks symptomatic benefit in both arms

Fx=fraction; OD=once daily; BD=twice daily; ref=reference, pts=patients, QOL=quality of life

Salient points

- Various hypofractionated doses used
- High efficacy, low sideeffects
- Side-effects increase with higher dose
- Median survival around 6 months
- Treatment duration preferably short
- •Duration of side effects and QoL should be part of well designed trials in future

Radiotherapy and Oncology 126 (2018) 558-567



Contents lists available at ScienceDirect

Radiotherapy and Oncology

journal homepage: www.thegreenjournal.com



Systematic review

Palliative radiotherapy for locally advanced non-metastatic head and neck cancer: A systematic review



Muhammad Shahid Iqbal ^{a,*}, Charles Kelly ^a, Josef Kovarik ^a, Bojidar Goranov ^b, Ghazia Shaikh ^a, David Morgan ^c, Werner Dobrowsky ^a, Vinidh Paleri ^d

* Department of Clinical Oncology, Northern Centre for Cancer Care, The Newcastle upon Tyne Hospitals NHS Foundation Trust; ¹Department of Clinical Oncology, Derriford Hospital, Plymouth; ⁵Department of Physics, Northern Centre for Cancer Care, The Newcastle upon Tyne Hospitals NHS Foundation Trust; and ⁴The Royal Marsden NHS Foundation Trust, London Initial Kinadon.

Other cancer directed care

Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study

Publication: Journal of Clinical Oncology • Volume 41, Number 2 • https://doi.org/10.1200/JCO.22.01015

- Chemotherapy alone or concurrent with RT
- Metronomic chemotherapy single/ multiple drug(s)
- Immunotherapy alone or in combination with other modalities

Treatment related symptoms



- Mucositis
- Dermatitis
- Xerostomia
- Subcutaneous fibrosis
- Lymphoedema
- Functional deficits
- Osteoradionecrosis


SPECIAL CARE IN DENTISTRY

Radiotherapy-induced oral morbidities in head and neck cancer patients


Sudhir Bhandari 🔀 Bhavita Wadhwa Soni, Amit Bahl, Sushmita Ghoshal

First published: 07 May 2020 | https://doi.org/10.1111/scd.12469 | Citations: 35





Oral and dental care protocol



Oral and dental care before radiotherapy: Guidelines and development of a time-bound protocol

Bhandari, Sudhir; Soni, Bhavita W; Jamwal, Ankush; Ghoshal, Sushmita


Indian Journal of Cancer59(2):159-169, Apr-Jun 2022.

doi: 10.4103/ijc.IJC 871 20

The scope of oral care in HNC patients. Day 1 is the patients' first visit to the oral health care facility after diagnosis of the disease has been made irrespective of the treatment pathway. Red Flags are alert for the concerned team of dentists to address patients' oral issues before surgery and/or RT and post-treatment cancer cure



Debilty related symptoms



- Weight loss
- Malnutrition
- Halitosis
- Constipation
- Infections

Uncontrolled disease



- Futility of disease modifying treatment
- Best supportive treatment
- Caregivers to be trained and instructed
- Pain management
- Nutritional support

Nutrition in HN cancer

- Nutritional deficit common
- Weight loss at diagnosis is prognostic for survival & ability to tolerate treatment
- Cytokines responsible for cachexia
- Proper assessment & intervention required

Interventions:-

- Counselling & supplements
- Tube feeding for swallowing problems (tube dependence)
- Specialist SLP for swallowing exercises
- QoL assessment during follow up for appropriate interventions

INTEGRATING ONCOLOGY & PALLIATIVE CARE



Welcome to the EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY, the leading European professional organisation for medical oncology.

How can we help you?

SEARCH

Conferences Career Development **Policy OncologyPRO** About Us | Membership | Guidelines | Research Patients ESMO / PATIENTS / DESIGNATED CENTRES OF INTEGRATED ONCOLOGY AND PALLIATIVE CARE Department Of Radiotherapy, Regional Cancer Centre, Pgimer, Chandigarh, India Department Of Radiotherapy, Regional f y 🖾 G+ in 💝 Patient Guides Cancer Centre, Pgimer, Chandigarh Personalised Medicine Explained ESMO Designated Centre of Integrated Oncology and Palliative Care Getting the Most out of Your Contact Sushmita Ghoshal Chakrabarti Oncologist person » Designated Centres of Postgraduate Institute of Medical Education and Research Sector 12 Integrated Oncology and Chandigarh **Palliative Care** Chandigarh U.T. Address 160012 Designated Centres Survey

Conclusions

- Scope of palliative medicine for all stages of head & neck cancers
- Concept of total care comes from palliative medicine
- Assessment of symptoms, tailoring of cancer directed treatment & supportive care needed
- Early integration of oncology & palliative care improves QoL of patients & caregivers, satisfaction of healthcare professionals

Thank you



To cure sometimes,

To relieve often,

To comfort

always....